{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:19:51Z","timestamp":1770268791587,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ando.2021.11.005","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T12:05:52Z","timestamp":1638533152000},"page":"9-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimal testosterone level to improve symptoms of hypogonadism without causing dopa-testotoxicosis in male macroprolactinoma"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7566-5427","authenticated-orcid":false,"given":"Ozge","family":"Telci Caklili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse Merve","family":"Ok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zulal","family":"Istemihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Selcukbiricik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sema","family":"Yarman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2021.11.005_bib0200","doi-asserted-by":"crossref","first-page":"e5833","DOI":"10.1097\/MD.0000000000005833","article-title":"Surgical treatment for male prolactinoma: a retrospective study of 184 cases","volume":"96","author":"Song","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.ando.2021.11.005_bib0205","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","volume":"148","author":"Colao","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2021.11.005_bib0210","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMcp025334","article-title":"Prolactinoma","volume":"349","author":"Schlechte","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2021.11.005_bib0215","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2021.11.005_bib0220","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.11.005_bib0225","first-page":"123","article-title":"Clinical practice guideline for the diagnosis and treatment of hyperprolactinemia","volume":"82","author":"Salazar-L\u00f3pez-Ortiz","year":"2014","journal-title":"Ginecol Obstet Mex"},{"key":"10.1016\/j.ando.2021.11.005_bib0230","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jocn.2015.03.058","article-title":"Update on prolactinomas. Part 1: clinical manifestations and diagnostic challenges","volume":"22","author":"Wong","year":"2015","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.ando.2021.11.005_bib0235","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/edrv-13-2-220","article-title":"Dopamine agonists and pituitary tumor shrinkage","volume":"13","author":"Bevan","year":"1992","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2021.11.005_bib0240","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2265.1997.1300952.x","article-title":"Treatment of macroprolactinoma with cabergoline: a study of 85 patients","volume":"46","author":"Ferrari","year":"1997","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2021.11.005_bib0245","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1530\/EJE-14-0848","article-title":"Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma","volume":"172","author":"Molitch","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2021.11.005_bib0250","article-title":"Optimal effective doses of cabergoline and bromocriptine and valvular lesions in men with prolactinomas","volume":"33","author":"Yarman","year":"2012","journal-title":"Neuroendocrinol Lett"},{"key":"10.1016\/j.ando.2021.11.005_bib0255","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s12020-018-1703-4","article-title":"Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses","volume":"62","author":"Ara\u00fajo","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2021.11.005_bib0260","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","article-title":"Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study","volume":"85","author":"Garcia-Ruiz","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ando.2021.11.005_bib0265","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2021.11.005_bib0270","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2018-02202","article-title":"Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study","volume":"104","author":"Dogansen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.11.005_bib0275","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/humrep\/deg172","article-title":"Macroprolactinaemia associated with prolactin adenoma","volume":"18","author":"Mounier","year":"2003","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ando.2021.11.005_bib0280","first-page":"5","article-title":"Macroprolactinemia in a patient with invasive macroprolactinoma: a case report and minireview","author":"Elenkova","year":"2013","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.ando.2021.11.005_bib0285","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.surneu.2003.08.036","article-title":"Giant pituitary tumors: a study based on surgical treatment of 118 cases","volume":"61","author":"Goel","year":"2004","journal-title":"Surg Neurol"},{"key":"10.1016\/j.ando.2021.11.005_bib0290","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1227\/01.NEU.0000255459.14764.BA","article-title":"Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients","volume":"60","author":"Mortini","year":"2007","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ando.2021.11.005_bib0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2251-6581-12-3","article-title":"Giant prolactinoma: case report and review of literature","volume":"12","author":"Rahmanian","year":"2013","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.ando.2021.11.005_bib0300","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline","volume":"95","author":"Bhasin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.11.005_bib0305","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and management of testosterone deficiency: AUA guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.ando.2021.11.005_bib0310","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2265.2012.04351.x","article-title":"Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome","volume":"77","author":"Iglesias","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2021.11.005_bib0315","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s11102-013-0497-x","article-title":"Male prolactinomas presenting with normal testosterone levels","volume":"17","author":"Shimon","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2021.11.005_bib0320","first-page":"530","article-title":"Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas","volume":"131","author":"Bhansali","year":"2010","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ando.2021.11.005_bib0325","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.11.005_bib0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-015-0006-4","article-title":"Management of macroprolactinomas","volume":"1","author":"Tirosh","year":"2015","journal-title":"Clin Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2021.11.005_bib0335","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/cen.12242","article-title":"Giant prolactinomas: the therapeutic approach","volume":"79","author":"Moraes","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2021.11.005_bib0340","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12020-015-0791-7","article-title":"Giant prolactinomas: are they really different from ordinary macroprolactinomas?","volume":"52","author":"Espinosa","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2021.11.005_bib0345","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11102-017-0806-x","article-title":"Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal","volume":"20","author":"Teixeira","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2021.11.005_bib0350","doi-asserted-by":"crossref","first-page":"R88","DOI":"10.1530\/EC-18-0030","article-title":"Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist","volume":"7","author":"Athanasoulia-Kaspar","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2021.11.005_bib0355","series-title":"Hypersexuality in men with prolactinomas treated with dopamine agonists","author":"Bancos","year":"2017"},{"key":"10.1016\/j.ando.2021.11.005_bib0360","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJM197810192991602","article-title":"Prolactin-secreting tumors and hypogonadism in 22 men","volume":"299","author":"Carter","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2021.11.005_bib0365","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1210\/jc.2007-1972","article-title":"Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study","volume":"93","author":"Wu","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.11.005_bib0370","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11102-014-0563-z","article-title":"Hypopituitarism patterns and prevalence among men with macroprolactinomas","volume":"18","author":"Tirosh","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2021.11.005_bib0375","doi-asserted-by":"crossref","first-page":"e4551","DOI":"10.1210\/clinem\/dgaa650","article-title":"Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on cabergoline","volume":"105","author":"Sehemby","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.11.005_bib0380","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.11.005_bib0385","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2265.2007.02905.x","article-title":"Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy","volume":"67","author":"Colao","year":"2007","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2021.11.005_bib0390","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11102-016-0708-3","article-title":"Withdrawal of dopamine agonist therapy in prolactinomas: in which patients and when?","volume":"19","author":"Dogansen","year":"2016","journal-title":"Pituitary"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426621011008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426621011008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:54:05Z","timestamp":1757717645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426621011008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0003426621011008"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2021.11.005","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal testosterone level to improve symptoms of hypogonadism without causing dopa-testotoxicosis in male macroprolactinoma","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2021.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}